Loading
A phase 2 trial of Aglatimagene besadenovec in prostate cancer, run by Candel Therapeutics, Inc., active and no longer recruiting.
Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) is a phase 2 interventional study registered as NCT02768363 by Candel Therapeutics, Inc., with 187 participants enrolled, started 2016-05 and due to reach its primary completion in 2024-11. Interventions recorded: aglatimagene besadenovec, placebo, valacyclovir. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Aglatimagene besadenovec, Candel Therapeutics, Prostate cancer.
Shares Aglatimagene besadenovec, Candel Therapeutics, Prostate cancer.
Shares Localised prostate cancer, very low and low risk, Prostate cancer.
Shares Localised prostate cancer, very low and low risk, Prostate cancer.
Shares Localised prostate cancer, very low and low risk, Prostate cancer.
Shares Localised prostate cancer, very low and low risk, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/